Related references
Note: Only part of the references are listed.Evidence for Associations Between Th1/Th17 Hybrid Phenotype and Altered Lipometabolism in Very Severe Graves Orbitopathy
Sijie Fang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib
Ryo Amagai et al.
JOURNAL OF DERMATOLOGY (2020)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy
Moyuka Irimada et al.
JOURNAL OF DERMATOLOGY (2019)
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
Taku Fujimura et al.
Oncotarget (2018)
IL-17A+GM-CSF+ Neutrophils Are the Major Infiltrating Cells in Interstitial Lung Disease in an Autoimmune Arthritis Model
Oh Chan Kwon et al.
FRONTIERS IN IMMUNOLOGY (2018)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Elevated circulating levels of the interferon-γ- induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still's disease
Jae Ho Han et al.
SCIENTIFIC REPORTS (2017)
Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma
Sadanori Furudate et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia
S. Colafrancesco et al.
IMMUNOLOGIC RESEARCH (2014)
Citrullination alters the inflammatory properties of chemokines in inflammatory arthritis
Jenny Buckland
Nature Reviews Rheumatology (2014)
Comparison of Interleukin-17-Producing Cells in Different Clinical Types of Alopecia Areata
Genichi Tojo et al.
DERMATOLOGY (2013)
Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy
Hanne Van Gorp et al.
MOLECULAR IMMUNOLOGY (2010)